London, UK; 11th September 2007 - Cancer Research Technology Ltd (CRT), the specialist oncology development and commercialisation company, today announces a new technology licence agreement and collaboration between researchers at UCL (University College London) and Novozymes Delta UK Ltd (Nottingham, UK) to develop novel anti-cancer therapeutics.
